CN109453162A - Application, pharmaceutical composition and application of the amentoflavone in preparation protection and/or reparation nerve cell drug - Google Patents
Application, pharmaceutical composition and application of the amentoflavone in preparation protection and/or reparation nerve cell drug Download PDFInfo
- Publication number
- CN109453162A CN109453162A CN201910011283.2A CN201910011283A CN109453162A CN 109453162 A CN109453162 A CN 109453162A CN 201910011283 A CN201910011283 A CN 201910011283A CN 109453162 A CN109453162 A CN 109453162A
- Authority
- CN
- China
- Prior art keywords
- amentoflavone
- cell
- pharmaceutical composition
- present
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention provides application of the amentoflavone in preparation protection and/or reparation nerve cell drug; belong to pharmaceutical technology field; the amentoflavone can repair nerve cell; improve nervous function protecting and/or repairing in nerve cell, has the characteristics that curative for effect, effect is stable and toxic side effect is small.
Description
Technical field
The invention belongs to pharmaceutical technology fields, and in particular to amentoflavone is in preparation protection and/or repairs nerve carefully
Application, pharmaceutical composition and application in born of the same parents' drug.
Background technique
Current clinically used reparation nerve cell, the drug for improving nervous function includes: (1) anticholinesterase:
Also known as anticholinesterase, by the reversible inhibition to acetylcholinesterase, reaching makes acetylcholine (Ach) at cynapse
Accumulation, extend and increase the effect of acetylcholine.Central nervous system cholinergic pathway is at memory and cognitive information
Reason, storage center, enhancing cholinergic transmitter system function be treat AD important method, such drug to delay disease process,
Improve clinical symptoms have clear effect, be currently the choice drug of AD, at the same be also applied for vascular dementia, dementia with Lewy body,
Parkinson's disease dementia and brain trauma dementia etc..1. donepezil: the inhibition with high selectivity, invertibity acetylcholinesterase
Effect, long-term use can improve AD and VaD Patients ' Cognitive situation and activity of daily living.2. Rivastigmine: can double inhibition second
Acetylcholinesterase and butyrylcholine esterase, clinical application obtain good efficacy, treat common medicine at present for AD, need when clinical application
Gradually dosage.3. galanthamine: play the role of acetylcholine esterase inhibition and adjust choline receptor, to improve light, moderate AD and
VaD cognitive function of patients and activity of daily living are effective.4. huperzine is by China scientific research personnel first from Huperziaceae plant
A kind of alkaloid of acquisition is extracted in serrate clubmoss herb, is reversible, selective acetylcholinesterase inhibitor, can be improved dementia patients
Symptom.(2) calcium antagonist: Nimodipine is slow channel voltage-dependent Ca2+Antagonist, it is silly for treating AD, VaD and Combination
It is slow-witted, clinical overall assessment and the cognitive function of patient can be improved, delay the development of VaD cognitive function of patients obstacle, reduce blood vessel
The generation of property adverse events.Other such as flunarizines, aplactan.(3) EAA antagonists: as glutamate receptor is short of money
Anti-agent memantine (easy times of Shen) can antagonism N- methyl-D-aspartate receptor, prevent glutamate discharge, reduce excitability
Toxic effect can be used for middle and advanced stage AD patient treatment.(4) cerebral blood flow (CBF) ergot bases: is increased by adrenolytic short of money
And energetic supersession, AD and VaD Patients ' Cognitive, emotion and self care ability may be improved.(5) pyrroles's gastral cavity class drug: can improve
Brain microcirculation helps energetic supersession, increases ability of learning and memory, long-term use and have small side effects.(6) promote intelligence agent: such as gamma-amino fourth
Acids (Piracetam).Other such as antioxidants (vitamin E, vitamin C and selegiline), non-steroidal anti-inflammatory drugs (Ah
Take charge of a woods, brufen etc.), polypeptide promote intelligence agent (brain resurrection), controversies in hormone replacement in the elderly etc. data show that cognition can be reduced
Obstacle risk, but related random contrast clinical trial evidence is insufficient, needs further to study confirmation.
Amentoflavone is the biflavone structure that two apiolins are connected to form by carbon-carbon bond, has document money
Material shows that amentoflavone has the function of anti-inflammatory, anti-oxidant, antimycotic, hypoglycemic, reducing blood lipid and antiulcer, but existing
There is not amentoflavone to have in technology and repair nerve cell, improves the report of nervous function effect.
Summary of the invention
In view of this, the purpose of the present invention is to provide amentoflavones in preparation protection and/or to repair nerve cell
Application in drug, the amentoflavone can repair nerve cell, and improvement nervous function is curative for effect, by the Honoka
After China fir biflavone is prepared into pharmaceutical composition, nerve cell can be repaired using pharmaceutical composition of the invention, improves neural function
Energy is curative for effect, effect is stablized and toxic side effect is small.
In order to achieve the above-mentioned object of the invention, the present invention the following technical schemes are provided:
The present invention provides application of the amentoflavone in preparation protection and/or reparation nerve cell drug.
The present invention provides a kind of pharmaceutical composition, the raw material including following parts by weight:
40~80 parts of amentoflavone, 5~25 parts of pulvinatabiflavone, 5~20 parts of apiolin and Quercetin 5~15
Part.
The present invention also provides application of the described pharmaceutical composition in preparation protection and/or reparation nerve cell drug.
The present invention also provides a kind of tablets, including above-mentioned technical proposal described pharmaceutical composition and lubricant.
Preferably, the lubricant includes superfine silica gel powder and/or magnesium stearate.
The present invention also provides a kind of capsules, including above-mentioned technical proposal described pharmaceutical composition and lubricant.
Preferably, the lubricant includes superfine silica gel powder and/or magnesium stearate.
The present invention also provides a kind of pills, including above-mentioned technical proposal described pharmaceutical composition and water-soluble base.
Preferably, the water-soluble base includes polyethylene glycol and/or glycerin gelatine.
The present invention also provides a kind of powders, including above-mentioned technical proposal described pharmaceutical composition, adhesive and lubricant.
Amentoflavone of the invention has the function of repairing nerve cell and improves nervous function, and the present invention is made
After at pharmaceutical composition, nerve cell can be repaired, improves nervous function, curative for effect, effect stabilization and toxic side effect
It is small.
Specific embodiment
The present invention provides application of the amentoflavone in preparation protection and/or reparation nerve cell drug.
The present invention is not particularly limited the source of the amentoflavone, using conventional commercial product, at this
In inventive embodiments, the preparation method of the amentoflavone preferably includes following steps:
(1) Selaginella tamariscina is obtained into extracting solution through 70%~90% ethanol solution refluxing extraction；
(2) extracting solution obtained in the step (1) is eluted through macroporous absorbent resin and polyamide resin column, is obtained
Eluent；
(3) eluent obtained in the step (2) is concentrated and dried, obtains Selaginella tamariscina general flavone；
(4) Selaginella tamariscina general flavone obtained in the step (3), 90-95% ethyl alcohol and silica G are mixed, is added after dry
The silicagel column installed；
(5) above-mentioned steps (4) described silicagel column is eluted by mobile phase of isopropanol-strong ammonia solution-water, it is double obtains amentotaxus
Flavones collection liquid；
(6) the amentoflavone collection liquid in the step (5) is recovered under reduced pressure, dried and recrystallized to get Honoka
China fir biflavone.
The Selaginella tamariscina through 70%~90% ethanol solution refluxing extraction, is obtained extracting solution by the present invention.The present invention is to described
The source of Selaginella tamariscina is not particularly limited, using conventional commercial product.
In the present invention, the volume fraction of the ethanol solution is 70%~90%, preferably 80%.
In the present invention, the number of the ethanol solution refluxing extraction is 1~4 time, preferably 2~3 times.
In the present invention, the time of the ethanol solution refluxing extraction be 0.5~3h, preferably 1~2h, more preferably
1.5h。
The present invention elutes the extracting solution through macroporous absorbent resin and polyamide resin column, obtains eluent.The present invention
The type and source of macroporous absorbent resin are not particularly limited, preferably AB-8, using conventional commercial product.
The present invention is not particularly limited the type of the polyamide resin column and source, is using conventional commercial product
It can.
Eluent of the present invention is concentrated and dried, and obtains Selaginella tamariscina general flavone.The present invention is concentrated and dried the eluent
Method is not particularly limited, the method being concentrated and dried using conventional eluent.
The present invention mixes the Selaginella tamariscina general flavone, 90-95% ethyl alcohol and silica G, spontaneously dries, the silica gel installed is added
Column.
In the present invention, ethanol consumption is preferably 1~8 times of amount, more preferably 5 times amounts with Selaginella tamariscina general flavone poidometer.
The present invention is not particularly limited the type of the silica G and source, using conventional commercial product.
The present invention is not particularly limited the type of the silicagel column and source, using conventional commercial product.
The present invention is that mobile phase elutes silicagel column described above to the isopropanol-strong ammonia solution-water, and it is double to obtain amentotaxus
Flavones collection liquid.
In the present invention, mobile phase isopropanol-strong ammonia solution-water volume ratio is preferably 13:1:1.
The amentoflavone collection liquid is recovered under reduced pressure, dried and recrystallized to get amentoflavone by the present invention.
The present invention is not particularly limited the method for being recovered under reduced pressure, drying and recrystallizing, using conventional method.In the present invention
In, the number of the recrystallization is preferably 2 times.
The present invention also provides a kind of pharmaceutical composition, the raw material including following parts by weight:
40~80 parts of amentoflavone, 5~25 parts of pulvinatabiflavone, 5~20 parts of apiolin and Quercetin 5~15
Part.
Pharmaceutical composition provided by the invention include parts by weight be 40~80 parts of amentoflavones, preferably 50~70
Part, more preferably 60 parts.The present invention is not particularly limited the source of the amentoflavone, using customary preparation methods system
Standby obtained amentoflavone uses conventional commercial product.Amentoflavone of the invention, which has, repairs nerve
Cell and the effect for improving nervous function.
Pharmaceutical composition provided by the invention include parts by weight be 5~25 parts of pulvinatabiflavones, preferably 10~
20 parts, more preferably 15 parts.The present invention is not particularly limited the source of the pulvinatabiflavone, using conventional preparation side
The pulvinatabiflavone that method is prepared or the commercial product using routine.Pulvinatabiflavone of the present invention
With xanthine oxidase is inhibited, promotes amentoflavone to repair nerve cell and improve the effect of nervous function.
Pharmaceutical composition provided by the invention includes that parts by weight are 5~20 parts of apiolins, preferably 8~16 parts, more excellent
It is selected as 15 parts.The present invention is not particularly limited the source of the apiolin, the celery being prepared using customary preparation methods
Element uses conventional commercial product.Apiolin of the present invention have it is anti-oxidant, inhibit xanthine oxidase simultaneously promote
Into the effect of amentoflavone protection nerve cell.
Pharmaceutical composition provided by the invention includes that parts by weight are 5~15 parts of Quercetins, preferably 8~12 parts, more excellent
It is selected as 10 parts.The present invention is not particularly limited the source of the Quercetin, the quercitrin being prepared using customary preparation methods
Element or the product for using conventional commercial.Quercetin of the invention has regulation PI3K/Akt signal path, promotes amentotaxus
Protective effect of the biflavone to nerve cell.
The present invention also provides application of the described pharmaceutical composition in preparation protection and/or reparation nerve cell drug.
The present invention also provides a kind of tablets, including described pharmaceutical composition and lubricant.The present invention is to the tablet
Preparation method is not particularly limited, using the conventional preparation method for preparing tablet.
The present invention is not particularly limited the type of the lubricant and source, preferably superfine silica gel powder and/or stearic acid
Magnesium, using conventional commercial product.
The present invention also provides a kind of capsules, including described pharmaceutical composition and lubricant.The present invention is to the capsule
The preparation method of agent is not particularly limited, using the conventional preparation method for preparing capsule.
The present invention is not particularly limited the type of the lubricant and source, preferably superfine silica gel powder and/or stearic acid
Magnesium, using conventional commercial product
The present invention also provides a kind of pills, including described pharmaceutical composition and water-soluble base.The present invention is to described
The preparation method of pill is not particularly limited, using the conventional preparation method for preparing pill.
The present invention is not particularly limited the type of the water-soluble base and source, preferably polyethylene glycol and/or sweet
Oily gelatin, using conventional commercial product.
The present invention also provides a kind of powders, including above-mentioned technical proposal described pharmaceutical composition, adhesive and lubricant.
The present invention is not particularly limited the preparation method of the powder, using the conventional preparation method for preparing powder.
The present invention is not particularly limited the type of described adhesive and source, preferably dextrin, is produced using conventional commercial
Product.
The present invention is not particularly limited the type of the lubricant and source, using conventional commercial product.
Below in conjunction with the embodiment in the present invention, technical solution provided by the invention is clearly and completely described.
Obviously, described embodiments are only a part of the embodiments of the present invention, instead of all the embodiments.Based in the present invention
Embodiment, every other embodiment obtained by those of ordinary skill in the art without making creative efforts, all
Belong to the scope of protection of the invention.
Embodiment 1
Amentoflavone 120g, pulvinatabiflavone 30g, apiolin 30g and Quercetin 20g mix to get drug
Composition；By aforementioned pharmaceutical compositions 200g, dextrin 100g, mixes, pelletized using conventional wet lay, dry, stiffened fatty acid magnesium
1.5g mixes, is pressed into 1000, and amentoflavone 0.12g is contained in every.
Embodiment 2
Amentoflavone 160g, pulvinatabiflavone 10g, apiolin 10g and Quercetin 20g mix to get drug
Composition；Aforementioned pharmaceutical compositions plus starch 80g are mixed, superfine silica gel powder 20g, magnesium stearate 2g is added and mixes, according to routine
The preparation method for preparing capsule prepares capsule 1000, contains amentoflavone 0.16g in every capsule.
Embodiment 3
Amentoflavone 90g, pulvinatabiflavone 10g, apiolin 10g and Quercetin 5g mix to get medicine group
Object is closed, addition polymerization ethylene glycol 6000500g, sets in pill dripping machine in aforementioned pharmaceutical compositions, heating, prepares dripping pill using conventional
Preparation method prepares dripping pill 5000, every grain pill 0.018g containing amentoflavone.
Embodiment 4
Amentoflavone 145g, pulvinatabiflavone 20g, apiolin 20g and Quercetin 15g mix to get medicine
Compositions, in aforementioned pharmaceutical compositions plus dextrin 800g, magnesium stearate 2g are mixed, using the conventional preparation side for preparing powder
Method prepares powder, and every bag in terms of 1g, contains amentoflavone 0.145g in every bag of powder.
Embodiment 5
The preparation method of amentoflavone: by chromatogram of Herba Selaginellae 5000g through 80% alcohol reflux 3 times, 3h is extracted, is mentioned
Liquid is taken, passes through AB-8 and polyamide resin column respectively, collects eluent, is concentrated and dried up to Selaginella tamariscina general flavone.Take Selaginella tamariscina always yellow
Ketone 50g, 90% ethyl alcohol 250ml dissolution, admixes silica G 50g mixing, spontaneously dries, the silicagel column installed is added, with isopropyl
Alcohol-strong ammonia solution-water (13:1:1) is mobile phase elution, collects amentoflavone, is recovered under reduced pressure, dry, is recrystallized 2 times,
Up to amentoflavone monomer 10g.
It takes and is added in the water of 50ml according to the amentoflavone 5g that above-mentioned preparation method is prepared, being prepared into concentration is
The amentoflavone solution of 0.1g/ml.20 test mices (half male and half female) are taken, by the daily gastric infusion of 40mL/kg 1 time,
Successive administration 14 days, no animal dead；Whole animal subject hair colors, state, autonomic activities, breathing, mouth and nose point are observed after administration
Secretion, diet and urine and stool are showed no abnormal response；Animal is put to death after 14 days, dissection internal organs are showed no exception, and weight gradually increases.
Cognitive disorder model mice each 20 are given caused by hyoscine, sodium nitrite and 45% ethyl alcohol, control group 10
Only, experimental group 10, wherein experimental group gives the amentoflavone of 50mg/kg dosage；Observe the wrong reaction time of mouse
With diving tower errors number.As a result as shown in the table:
1 amentoflavone of table is to the wrong reaction time of hyoscine mouse cognitive disorder and the shadow of diving tower errors number
It rings
| Group | The wrong reaction time (second) | Diving tower errors number (secondary) |
| Control group | 190±13 | 6±0.9 |
| Experimental group | 80±9 | 2±0.2 |
Above-described embodiment the result shows that: amentoflavone to the memory dysfunction mouse wrong response latency extend
It reduces with diving tower errors number, and then is arrived in pathologic examination, amentoflavone is to small caused by three kinds of pathogenic factors
The morphological change that the disorder of mouse Hippocampus cell arrangement, sparse and cell quantity significantly reduce, which has, preferably improves and rehabilitates work
With；It can be seen that the hippocampus of mice area cell quantity after treatment increases under light microscopic, cell arrangement is neat, fine and close, hippocampus
Tissue morphology tends to be complete.
Embodiment 6
The first step, cell culture；Culture cell is human neuroblastoma cells SH-SY5Y, using containing 10% tire ox blood
The low-sugar type culture medium of (fatal bovine serum, FBS) clearly, in 37 DEG C, 5% CO2It is cultivated in incubator；
Second step, composition tablet prepared by embodiment 1 act on normal cell；When SH-SY5Y cell is in logarithm life
When long-term, cell concentration is 1.0 × 105, the example 1 group that final concentration of 10,40,80 μ g/ml is added closes object tablet, 37
DEG C, 5%CO2It is cultivated for 24 hours in incubator；Supernatant is siphoned away, 150 μ L DMSO, abundant dissolving crystallized, microplate reader 490nm is added,
Each hole absorption value A is measured, cell survival rate is calculated, cell survival rate is as shown in the following Table 2；
Third step prepares okadaic acid, A β25-35Solution, packing, -20 DEG C save backup；
4th step establishes damaged cell model；When SH-SY5Y cell is in logarithmic growth phase, cell concentration be 1.0 ×
105, 96 orifice plates are seeded to, sample well is separately added into final concentration of 420 μm of ol/L hydrogen peroxide, the final concentration of ridge 35nmol/L
Field acid, final concentration of 40 μm of ol/LA β25-35, at 37 DEG C, 5%CO2It is cultivated in incubator for 24 hours, cell survival rate 50%；
5th step, protection of the composition tablet to damaging cells；When cell is in logarithmic growth phase, cell concentration is
1.0×105, it is seeded to 96 orifice plates, the example 1 group of cell and final concentration of 10,40,80 μ g/ml are closed object tablet and is incubated in advance
After 12 hours, the final concentration of 420 μm of ol/L hydrogen peroxide of damage factor are added, continue culture for 24 hours, mtt assay measures cell survival
Rate, cell survival rate is as shown in following table 2；The result reflects protective effect of the composition tablet to damaged nerve cells；
6th step, reparation of the composition tablet to damaging cells；When cell is in logarithmic growth phase, cell concentration is
1.0×105, 96 orifice plates are seeded to, final concentration of 420 μm of ol/L hydrogen peroxide are added in cell, cultivate 12h, discard supernatant liquid, add
The example 1 group for entering final concentration of 10,40,80 μ g/ml closes object tablet, continues culture for 24 hours, and mtt assay measures cell survival rate, carefully
Born of the same parents' survival rate is as shown in following table 2；The result reflects repair of the composition tablet to damaged nerve cells；
The cell SH-SY5Y is human neuroblastoma cells, (being purchased from Cell Bank of Chinese Academy of Sciences)；
The culture medium is low sugar DMEM culture medium.
Influence of 2 embodiment of table, the 1 various concentration composition tablet to cell survival rate
Embodiment 7
The first step, cell culture；Culture cell is human neuroblastoma cells SH-SY5Y, using containing 10% tire ox blood
The low-sugar type culture medium of (fatal bovine serum, FBS) clearly, in 37 DEG C, 5% CO2It is cultivated in incubator；
Second step, composition capsule prepared by embodiment 2 act on normal cell；When SH-SY5Y cell is in logarithm life
When long-term, cell concentration is 1.0 × 105, 2 composition capsule of embodiment of final concentration of 10,40,80 μ g/ml is added, 37
DEG C, 5%CO2It is cultivated for 24 hours in incubator；Supernatant is siphoned away, 150 μ LDMSO are added, abundant dissolving crystallized, microplate reader 490nm is surveyed
Fixed each hole absorption value A, calculates cell survival rate, and cell survival rate is as shown in the following Table 3；
Third step prepares okadaic acid, A β25-35Solution, packing, -20 DEG C save backup；
4th step establishes damaged cell model；When SH-SY5Y cell is in logarithmic growth phase, cell concentration be 1.0 ×
105, 96 orifice plates are seeded to, sample well is separately added into final concentration of 420 μm of ol/L hydrogen peroxide, the final concentration of ridge 35nmol/L
Field acid, final concentration of 40 μm of ol/LA β25-35, at 37 DEG C, 5%CO2It is cultivated in incubator for 24 hours, cell survival rate 50%；
5th step, the protection of composition capsule prepared by embodiment 2 to damaging cells；When cell is in logarithmic growth phase
When, cell concentration is 1.0 × 105, 96 orifice plates are seeded to, cell is combined with the embodiment 2 of final concentration of 10,40,80 μ g/ml
After composite capsule is incubated for 12 hours in advance, the final concentration of 35nmol/L okadaic acid of damage factor is added, continues culture for 24 hours, mtt assay is surveyed
Determine cell survival rate, cell survival rate is as shown in the following Table 3；The result reflects protection of the composition capsule to damaged nerve cells
Effect；
6th step, the reparation of composition capsule prepared by embodiment 2 to damaging cells；When cell is in logarithmic growth phase
When, cell concentration is 1.0 × 105, 96 orifice plates are seeded to, final concentration of 35 nmol/L okadaic acid is added in cell, cultivates 12h, abandons
Supernatant is removed, 2 composition capsule of embodiment of final concentration of 10,40,80 μ g/ml is added, continues culture for 24 hours, mtt assay measurement is thin
Born of the same parents' survival rate, cell survival rate are as shown in the following Table 3；The result reflects that composition capsule makees the reparation of damaged nerve cells
With；
The cell SH-SY5Y is human neuroblastoma cells, (being purchased from Cell Bank of Chinese Academy of Sciences)；
The culture medium is low sugar DMEM culture medium.
Influence of 3 embodiment of table, the 2 various concentration composition capsule to cell survival rate
Embodiment 8
The first step, cell culture；Culture cell is human neuroblastoma cells SH-SY5Y, using containing 10% tire ox blood
The low-sugar type culture medium of (fatal bovine serum, FBS) clearly, in 37 DEG C, 5% CO2It is cultivated in incubator；
Second step, composition dripping agent prepared by embodiment 3 act on normal cell；When SH-SY5Y cell is in logarithm
When growth period, cell concentration is 1.0 × 105, 3 composition dripping of embodiment of final concentration of 10,40,80 μ g/ml is added,
37 DEG C, 5%CO2It is cultivated for 24 hours in incubator；Supernatant is siphoned away, 150 μ LDMSO, abundant dissolving crystallized, microplate reader 490nm is added,
Each hole absorption value A is measured, cell survival rate is calculated, cell survival rate is as shown in the following Table 4；
Third step prepares okadaic acid, A β25-35Solution, packing, -20 DEG C save backup；
4th step establishes damaged cell model；When SH-SY5Y cell is in logarithmic growth phase, cell concentration be 1.0 ×
105, 96 orifice plates are seeded to, sample well is separately added into final concentration of 420 μm of ol/L hydrogen peroxide, the final concentration of ridge 35nmol/L
Field acid, final concentration of 40 μm of ol/LA β25-35, at 37 DEG C, 5%CO2It is cultivated in incubator for 24 hours, cell survival rate 50%；
5th step, the protection of composition dripping prepared by embodiment 3 to damaging cells；When cell is in logarithmic growth phase
When, cell concentration is 1.0 × 105, 96 orifice plates are seeded to, cell is combined with the embodiment 3 of final concentration of 10,40,80 μ g/ml
After composition dropping pills are incubated for 12 hours in advance, the final concentration of 40 μm of ol/LA β of damage factor are added25-35Okadaic acid continues culture for 24 hours,
Mtt assay measures cell survival rate, and cell survival rate is as shown in the following Table 4；The result reflects that composition dripping is thin to injuring nerve
The protective effect of born of the same parents；
6th step, the reparation of composition dripping prepared by embodiment 3 to damaging cells；When cell is in logarithmic growth phase
When, cell concentration is 1.0 × 105, 96 orifice plates are seeded to, final concentration of 40 μm of ol/LA β are added in cell25-35, 12h is cultivated, is abandoned
Supernatant is removed, 3 composition dripping of embodiment of final concentration of 10,40,80 μ g/ml is added, continues culture for 24 hours, mtt assay measurement
Cell survival rate, cell survival rate are as shown in the following Table 4；The result reflects that composition dripping makees the reparation of damaged nerve cells
With；
The cell SH-SY5Y is human neuroblastoma cells, (being purchased from Cell Bank of Chinese Academy of Sciences)；
The culture medium is low sugar DMEM culture medium.
Influence of 4 embodiment of table, the 3 various concentration composition dripping to cell survival rate
As can be seen from the above embodiments, amentoflavone provided by the invention can repair nerve cell, improve mind
Curative for effect through function, effect is stablized and toxic side effect is small；After the amentoflavone is prepared into pharmaceutical composition, benefit
Nerve cell can be repaired with pharmaceutical composition of the invention, it is curative for effect to improve nervous function.
The above is only a preferred embodiment of the present invention, it is noted that for the ordinary skill people of the art
For member, various improvements and modifications may be made without departing from the principle of the present invention, these improvements and modifications are also answered
It is considered as protection scope of the present invention.
Claims (10)
1. application of the amentoflavone in preparation protection and/or reparation nerve cell drug.
2. a kind of pharmaceutical composition, which is characterized in that the raw material including following parts by weight:
40~80 parts of amentoflavone, 5~25 parts of pulvinatabiflavone, 5~20 parts of apiolin and 5~15 parts of Quercetin.
3. application of the pharmaceutical composition as claimed in claim 2 in preparation protection and/or reparation nerve cell drug.
4. a kind of tablet, including pharmaceutical composition as claimed in claim 2 and lubricant.
5. tablet according to claim 4, which is characterized in that the lubricant includes superfine silica gel powder and/or magnesium stearate.
6. a kind of capsule, including pharmaceutical composition as claimed in claim 2 and lubricant.
7. capsule according to claim 5, which is characterized in that the lubricant includes superfine silica gel powder and/or magnesium stearate.
8. a kind of pill, including pharmaceutical composition as claimed in claim 2 and water-soluble base.
9. pill according to claim 6, which is characterized in that the water-soluble base includes polyethylene glycol and/or sweet
Oily gelatin.
10. a kind of powder, including pharmaceutical composition as claimed in claim 2, adhesive and lubricant.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910011283.2A CN109453162B (en) | 2019-01-07 | 2019-01-07 | Application of amentoflavone in preparation of medicine for protecting and/or repairing nerve cells, medicine composition and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910011283.2A CN109453162B (en) | 2019-01-07 | 2019-01-07 | Application of amentoflavone in preparation of medicine for protecting and/or repairing nerve cells, medicine composition and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109453162A true CN109453162A (en) | 2019-03-12 |
| CN109453162B CN109453162B (en) | 2020-10-09 |
Family
ID=65616110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910011283.2A Active CN109453162B (en) | 2019-01-07 | 2019-01-07 | Application of amentoflavone in preparation of medicine for protecting and/or repairing nerve cells, medicine composition and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109453162B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112263573A (en) * | 2020-10-23 | 2021-01-26 | 宁夏医科大学 | Application of amentoflavone in preparation of medicine for treating glioma |
| CN115850226A (en) * | 2022-12-01 | 2023-03-28 | 河南中医药大学 | Preparation method and application of diketone compound dysosma versipellis biflavone F and G |
| CN115850295A (en) * | 2022-12-01 | 2023-03-28 | 河南中医药大学 | Preparation method and application of diketone compound dysosma versipellis biflavone A-E |
| CN116270274A (en) * | 2023-04-14 | 2023-06-23 | 太和康美(北京)中医研究院有限公司 | Composition with water-oil coherent effect and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006001665A1 (en) * | 2004-06-28 | 2006-01-05 | Seoul National University Industry Foundation | Composition for preventing or treating acute or chronic degenerative brain diseases including flavonoid derivatives |
| CN101297823A (en) * | 2008-06-27 | 2008-11-05 | 赵全成 | Medicament for preventing and treating Alzheimer's disease |
| CN105106298A (en) * | 2015-09-09 | 2015-12-02 | 济南星懿医药技术有限公司 | Pharmaceutical composition with nerve cell protective effect |
-
2019
- 2019-01-07 CN CN201910011283.2A patent/CN109453162B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006001665A1 (en) * | 2004-06-28 | 2006-01-05 | Seoul National University Industry Foundation | Composition for preventing or treating acute or chronic degenerative brain diseases including flavonoid derivatives |
| CN101297823A (en) * | 2008-06-27 | 2008-11-05 | 赵全成 | Medicament for preventing and treating Alzheimer's disease |
| CN105106298A (en) * | 2015-09-09 | 2015-12-02 | 济南星懿医药技术有限公司 | Pharmaceutical composition with nerve cell protective effect |
Non-Patent Citations (3)
| Title |
|---|
| 张莲珠: "卷柏总黄酮及穗花杉双黄酮对认知障碍模型的治疗及可能作用", 《中国博士学位论文全文数据库医药卫生科技辑》 * |
| 梅全喜主编: "《香药 沉香》", 31 July 2016, 中国中医药出版社 * |
| 汪晓: "卷柏属植物黄酮类成分及其对机体免疫的影响", 《长春中医药大学学报》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112263573A (en) * | 2020-10-23 | 2021-01-26 | 宁夏医科大学 | Application of amentoflavone in preparation of medicine for treating glioma |
| CN115850226A (en) * | 2022-12-01 | 2023-03-28 | 河南中医药大学 | Preparation method and application of diketone compound dysosma versipellis biflavone F and G |
| CN115850295A (en) * | 2022-12-01 | 2023-03-28 | 河南中医药大学 | Preparation method and application of diketone compound dysosma versipellis biflavone A-E |
| CN115850226B (en) * | 2022-12-01 | 2024-01-26 | 河南中医药大学 | Preparation method and application of diketone compound dysosma versipellis biflavone F, G |
| CN115850295B (en) * | 2022-12-01 | 2024-01-26 | 河南中医药大学 | Preparation method and application of diketone compound dysosma versipellis biflavone A-E |
| CN116270274A (en) * | 2023-04-14 | 2023-06-23 | 太和康美(北京)中医研究院有限公司 | Composition with water-oil coherent effect and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109453162B (en) | 2020-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109453162A (en) | Application, pharmaceutical composition and application of the amentoflavone in preparation protection and/or reparation nerve cell drug | |
| CN102271694A (en) | Plant extract compositions for affecting sleep | |
| ES2720055T3 (en) | Pharmaceutical composition for treating and preventing degenerative neurological disorders, which contains, as an active ingredient, mixture extract of peony root bark, Chinese angelica root and gypsy herb root or a fraction thereof | |
| CN109045158A (en) | A kind of composition and preparation method and application containing NMN | |
| CN101849957B (en) | Application of Dendrobium officinale polysaccharide in preparation of medicine for preventing and treating hypertension and apoplexy | |
| CN101230003B (en) | Preparation method of salvia miltiorrhiza tanshinoate A | |
| CN101612316B (en) | Application of dendrobium officinale aqueous extract in preparing medicine for preventing and treating hypertension and apoplexy | |
| CN104138379A (en) | An anti-hypoxic pharmaceutical composition and applications thereof | |
| CN102631405A (en) | Compound apigenin nanoemulsion antihypertensive drug | |
| CN102188438A (en) | Application of acetagastrodine in preparing medicines to prevent and treat vascular dementia (VD) and Alzheimer disease (AD) | |
| CN103360456A (en) | Triterpenoid compounds, and preparation and application thereof | |
| CN102716135B (en) | Lupenone prevents in preparation or treats the application in the product of diabetes | |
| CN107648479A (en) | A kind of Chinese prescription and its product for being used to treat hypertension | |
| KR20190084248A (en) | How to relieve symptoms of PMS | |
| CN101474383A (en) | Preparation method of garlic total saponin as well as products produced thereby and application | |
| CN103156923A (en) | Application of humulus lupulus effective parts applied to preparation of medicine for preventing and improving depression and clinical symptoms | |
| CN100467025C (en) | Use of asiaticoside in preparation of medicines for diseases of cardio-cerebral blood vessels | |
| CN109172701A (en) | A kind of composition and preparation method and application containing NADH | |
| CN101164571A (en) | Application of active component of cape jasmine for treating senile dementia | |
| CN101199564A (en) | Application of sanchi flower total saponine in preparing treatment hypertension disease medicament | |
| US9592261B2 (en) | Compartment-specific plant extract combination of ginkgo biloba extract and ginseng extract having a tandem effect | |
| CN104524139B (en) | Allium wallichii extract and application thereof | |
| CN102727506B (en) | Rhizoma Gastrodiae Pai Lixin extract is in the application prepared in brain-protection drugs | |
| CN101696166B (en) | Preparation method for danshen root salvianolic acid A | |
| CN101804133A (en) | A kind ofly be used for the treatment of that development in children is slow, the Chinese medicine composition of mental retardation and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20230324 Address after: No. 1, Yucai Road, Jiyang District, Sanya City, Hainan Province, 572022, Business Incubation Base 7601, National University Science Park, Hainan Tropical Ocean University Patentee after: Hainan Aili Biotechnology Co.,Ltd. Address before: No.1 Yucai Road, Sanya City, Hainan Province, 572000 Patentee before: HAINAN TROPICAL OCEAN University |
|
| TR01 | Transfer of patent right |